Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis.

Kuusalo L, Puolakka K, Kautiainen H, Karjalainen A, Malmi T, Paimela L, Leirisalo-Repo M, Rantalaiho V; NEO-RACo Study Group.

Clin Rheumatol. 2017 Dec 26. doi: 10.1007/s10067-017-3958-1. [Epub ahead of print]

PMID:
29280011
2.

Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia.

Savola P, Brück O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, Kytölä S, Sokka-Isler T, Loughran TP, Leirisalo-Repo M, Mustjoki S.

Haematologica. 2018 Feb;103(2):304-312. doi: 10.3324/haematol.2017.175729. Epub 2017 Dec 7.

3.

One-Year Follow-up Study Detects Myocardial Changes with Cardiovascular Magnetic Resonance Tagging in Active Rheumatoid Arthritis.

Lehmonen L, Vuorinen AM, Koivuniemi R, Leirisalo-Repo M, Holmström M, Kivistö S, Kaasalainen T.

Acad Radiol. 2017 Nov 30. pii: S1076-6332(17)30444-0. doi: 10.1016/j.acra.2017.10.017. [Epub ahead of print]

PMID:
29199058
4.

Yersinia enterocolitica biotype 1A: a possible new trigger of reactive arthritis.

Tuompo R, Hannu T, Huovinen E, Sihvonen L, Siitonen A, Leirisalo-Repo M.

Rheumatol Int. 2017 Nov;37(11):1863-1869. doi: 10.1007/s00296-017-3816-0. Epub 2017 Sep 16.

PMID:
28918489
5.

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E; NEO-RACo Study Group.

PLoS One. 2017 Aug 25;12(8):e0183294. doi: 10.1371/journal.pone.0183294. eCollection 2017.

6.

The effect of cryotherapy on total antioxidative capacity in patients with active seropositive rheumatoid arthritis.

Hirvonen H, Kautiainen H, Moilanen E, Mikkelsson M, Leirisalo-Repo M.

Rheumatol Int. 2017 Sep;37(9):1481-1487. doi: 10.1007/s00296-017-3771-9. Epub 2017 Jul 11.

PMID:
28698947
7.

Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis.

Savola P, Kelkka T, Rajala HL, Kuuliala A, Kuuliala K, Eldfors S, Ellonen P, Lagström S, Lepistö M, Hannunen T, Andersson EI, Khajuria RK, Jaatinen T, Koivuniemi R, Repo H, Saarela J, Porkka K, Leirisalo-Repo M, Mustjoki S.

Nat Commun. 2017 Jun 21;8:15869. doi: 10.1038/ncomms15869.

8.

Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis.

Kuuliala K, Kuuliala A, Koivuniemi R, Kautiainen H, Repo H, Leirisalo-Repo M.

Arthritis Res Ther. 2017 Apr 11;19(1):75. doi: 10.1186/s13075-017-1278-0.

9.

Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.

Kuusalo L, Puolakka K, Kautiainen H, Karjalainen A, Malmi T, Yli-Kerttula T, Leirisalo-Repo M, Rantalaiho V; NEO-RACo Study Group.

Rheumatol Int. 2017 May;37(5):825-830. doi: 10.1007/s00296-017-3692-7. Epub 2017 Mar 13.

PMID:
28289873
10.

Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population.

Äyräväinen L, Leirisalo-Repo M, Kuuliala A, Ahola K, Koivuniemi R, Meurman JH, Heikkinen AM.

BMJ Open. 2017 Jan 31;7(1):e011916. doi: 10.1136/bmjopen-2016-011916.

11.

Impaired Akt Phosphorylation in Monocytes of Patients with Rheumatoid Arthritis.

Kuuliala K, Kuuliala A, Hämäläinen M, Koivuniemi R, Kautiainen H, Moilanen E, Repo H, Leirisalo-Repo M.

Scand J Immunol. 2017 Feb;85(2):155-161. doi: 10.1111/sji.12521.

12.

STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis.

Kuuliala K, Kuuliala A, Koivuniemi R, Kautiainen H, Repo H, Leirisalo-Repo M.

PLoS One. 2016 Dec 12;11(12):e0167975. doi: 10.1371/journal.pone.0167975. eCollection 2016.

13.

Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.

Levitsky A, Wick MC, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, van Vollenhoven RF, Rantalaiho V.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1065-1071. Epub 2016 Aug 31.

PMID:
27607411
14.

Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.

Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2.

PMID:
27494516
15.

Cardiac magnetic resonance imaging reveals frequent myocardial involvement and dysfunction in active rheumatoid arthritis.

Holmström M, Koivuniemi R, Korpi K, Kaasalainen T, Laine M, Kuuliala A, Leirisalo-Repo M, Kupari M, Kivistö S.

Clin Exp Rheumatol. 2016 May-Jun;34(3):416-23. Epub 2016 Apr 6.

PMID:
27050802
16.

Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety.

Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90. Epub 2016 Mar 25.

PMID:
27049733
17.

Renal diseases in patients with rheumatoid arthritis.

Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M.

Scand J Rheumatol. 2016 Oct;45(5):432-3. doi: 10.3109/03009742.2016.1143966. Epub 2016 Mar 7. No abstract available.

PMID:
26948659
18.

Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis.

Kuuliala K, Kuuliala A, Koivuniemi R, Oksanen S, Hämäläinen M, Moilanen E, Kautiainen H, Leirisalo-Repo M, Repo H.

PLoS One. 2015 Sep 9;10(9):e0137385. doi: 10.1371/journal.pone.0137385. eCollection 2015.

19.

Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.

Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group.

Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31.

PMID:
26324784
20.

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.

van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, Brock F, Franck-Larsson K.

Ann Rheum Dis. 2016 Jan;75(1):52-8. doi: 10.1136/annrheumdis-2014-205726. Epub 2015 Apr 14.

21.

Bloodstream infections among children with juvenile idiopathic arthritis: a prospective study from the onset of disease.

Salonen PH, Säilä H, Salonen JH, Vuorela M, Kautiainen H, Lyytikäinen O, Kauppi MJ, Leirisalo-Repo M, Repo H.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):979-83. Epub 2014 Dec 1.

PMID:
25436839
22.

Education, employment, absenteeism, and work disability in women with systemic lupus erythematosus.

Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H.

Scand J Rheumatol. 2015;44(2):157-62. doi: 10.3109/03009742.2014.953200. Epub 2014 Oct 29.

PMID:
25352057
23.

Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.

Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group.

J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1.

PMID:
25274892
24.

Impact of rheumatic diseases on oral health and quality of life.

Ahola K, Saarinen A, Kuuliala A, Leirisalo-Repo M, Murtomaa H, Meurman JH.

Oral Dis. 2015 Apr;21(3):342-8. doi: 10.1111/odi.12285. Epub 2014 Sep 22.

PMID:
25158802
25.

Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.

Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D.

Curr Med Res Opin. 2014 Nov;30(11):2139-49. doi: 10.1185/03007995.2014.942416. Epub 2014 Jul 30.

PMID:
25050591
26.

Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study.

Relas H, Kautiainen H, Puolakka K, Virta LJ, Leirisalo-Repo M.

Clin Rheumatol. 2014 Aug;33(8):1135-8. doi: 10.1007/s10067-014-2700-5. Epub 2014 Jun 7.

PMID:
24907035
27.

A review of serological tests to assist diagnosis of reactive arthritis: critical appraisal on methodologies.

Tuuminen T, Lounamo K, Leirisalo-Repo M.

Front Immunol. 2013 Dec 4;4:418. doi: 10.3389/fimmu.2013.00418. Review.

28.

What is the best treatment strategy for early RA?

Leirisalo-Repo M.

Best Pract Res Clin Rheumatol. 2013 Aug;27(4):523-36. doi: 10.1016/j.berh.2013.10.002. Epub 2013 Oct 7. Review.

PMID:
24315052
29.

Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, Hannonen P, Leirisalo-Repo M, Möttönen T; FIN-RACo Study Group.

Ann Rheum Dis. 2014 Apr;73(4):788-90. doi: 10.1136/annrheumdis-2013-204271. Epub 2013 Dec 2. No abstract available.

PMID:
24297374
30.

Smoking, disease activity, permanent damage and dsDNA autoantibody production in patients with systemic lupus erythematosus.

Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Miettinen A, Julkunen H.

Rheumatol Int. 2014 Mar;34(3):341-5. doi: 10.1007/s00296-013-2889-7. Epub 2013 Oct 30.

PMID:
24170320
31.

Work disability in Finnish patients with rheumatoid arthritis: a 15-year follow-up.

Tiippana-Kinnunen T, Paimela L, Peltomaa R, Kautiainen H, Laasonen L, Leirisalo-Repo M.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):88-94. Epub 2013 Oct 21.

PMID:
24143915
32.

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group.

Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.

PMID:
23908187
33.

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography.

Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.

Ann Rheum Dis. 2014 Oct;73(10):1819-25. doi: 10.1136/annrheumdis-2013-203425. Epub 2013 Jul 14.

PMID:
23852807
34.

Author's reply: To PMID 23244227.

Koivuniemi R, Leirisalo-Repo M.

Scand J Rheumatol. 2013;42(5):423-4. doi: 10.3109/03009742.2013.803698. Epub 2013 Jul 15. No abstract available.

PMID:
23848941
35.

Co-morbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up.

Tiippana-Kinnunen T, Kautiainen H, Paimela L, Leirisalo-Repo M.

Scand J Rheumatol. 2013;42(6):451-6. doi: 10.3109/03009742.2013.790073. Epub 2013 Jul 4.

PMID:
23826623
36.

Double-blind, randomized, placebo-controlled study of three-month treatment with the combination of ofloxacin and roxithromycin in recent-onset reactive arthritis.

Kuuliala A, Julkunen H, Paimela L, Peltomaa R, Kautiainen H, Repo H, Leirisalo-Repo M.

Rheumatol Int. 2013 Nov;33(11):2723-9. doi: 10.1007/s00296-013-2794-0. Epub 2013 Jun 20.

PMID:
23783643
37.

[Optimized treatment of a patient having rheumatoid arthritis and gout at the same time].

Nordström D, Leirisalo-Repo M, Petterson T.

Duodecim. 2013;129(10):1045-8. Finnish.

PMID:
23767136
38.

Frequency of and risk factors for symptomatic bone fractures in patients with systemic lupus erythematosus.

Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H.

Scand J Rheumatol. 2013;42(5):390-3. doi: 10.3109/03009742.2013.775331. Epub 2013 May 31.

PMID:
23721483
39.

Smoking and the risk of systemic lupus erythematosus.

Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H.

Clin Rheumatol. 2013 Aug;32(8):1219-22. doi: 10.1007/s10067-013-2224-4. Epub 2013 Mar 21.

PMID:
23515599
40.

Normal inflammasome activation and low production of IL-23 by monocyte-derived macrophages from subjects with a history of reactive arthritis.

Välimäki E, Aittomäki S, Karenko L, Kantonen J, Pettersson T, Turunen U, Matikainen S, Leirisalo-Repo M, Repo H.

Scand J Rheumatol. 2013;42(4):294-8. doi: 10.3109/03009742.2012.754940. Epub 2013 Feb 20.

PMID:
23425136
41.

Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.

Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Möttönen T; FIN-RACo Trial Group.

Ann Rheum Dis. 2013 May;72(5):786-8. doi: 10.1136/annrheumdis-2012-202737. Epub 2013 Jan 24. No abstract available.

PMID:
23349132
42.

Reactive arthritis following Salmonella infection: a population-based study.

Tuompo R, Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M.

Scand J Rheumatol. 2013;42(3):196-202. doi: 10.3109/03009742.2012.739201. Epub 2013 Jan 14.

PMID:
23311895
43.

Cardiovascular diseases in patients with rheumatoid arthritis.

Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M.

Scand J Rheumatol. 2013;42(2):131-5. doi: 10.3109/03009742.2012.723747. Epub 2012 Dec 18.

PMID:
23244227
44.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.

PMID:
22753402
45.

Signalling profiles of circulating leucocytes in patients recovered from reactive arthritis.

Alanärä T, Aittomäki S, Kuuliala K, Kuuliala A, Siitonen S, Leirisalo-Repo M, Repo H.

Scand J Rheumatol. 2012 Aug;41(4):267-74. doi: 10.3109/03009742.2012.664649. Epub 2012 Jun 1.

PMID:
22651550
46.

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):672-80. Epub 2011 Aug 31.

PMID:
21906431
47.

Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.

Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P.

Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29.

PMID:
21640044
48.

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D.

Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027.

49.

Impact of early radiographic remission on the 15-year radiographic outcome in patients with rheumatoid arthritis.

Tiippana-Kinnunen T, Laasonen L, Kautiainen H, Paimela L, Leirisalo-Repo M.

Scand J Rheumatol. 2011;40(4):263-8. doi: 10.3109/03009742.2010.547873. Epub 2011 Mar 21.

PMID:
21417549
50.

Wegener's granulomatosis in Finland in 1981-2000: risk of dialysis-dependent renal disease.

Takala JH, Kautiainen H, Finne P, Leirisalo-Repo M.

Scand J Rheumatol. 2011;40(4):283-8. doi: 10.3109/03009742.2010.533693. Epub 2011 Jan 13.

PMID:
21231798

Supplemental Content

Loading ...
Support Center